Skip to main content

Does Eylea and Eylea HD raise blood pressure?

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 1, 2023.

Official answer

by Drugs.com

Eylea and Eylea HD injections into the eye (intravitreal) are associated with a substantial but temporary increase in blood pressure in some patients.

One study of 201 patients reported that 72% of patients (n=144) had a mean systolic blood pressure increase of 10 mmHg or more and 46% (n=93) had a systolic BP increase of 20 mmHg or more. 11% (23 patients) had their blood pressure increase to over 200 mmHg which is associated with an increased risk of cardiovascular and cerebrovascular events. Blood pressure returned to near baseline levels approximately 5 minutes after the injection. The mean pulse rate also increased from 76 bpm to 80 bpm. Consider perioperative blood pressure monitoring or increased antihypertensive treatment in people at high risk for cardiovascular or cerebrovascular events undergoing intravitreal Eylea or Eylea HD injections.

Increases in intraocular pressure (the pressure inside the eye) have also been seen within 60 minutes of an injection of Eylea or Eylea HD. These pressure increases are usually temporary, but there is an increased risk of them becoming more sustained with repeated dosing of Eylea or Eylea HD. Because sustained intraocular pressure affects blood flow to the optic nerve and is associated with an increased risk of glaucoma, patients should be monitored and managed appropriately.

References
  • Summary Safety Review - EYLEA (aflibercept) - Assessing the Risk of Side Effects Outside the Eye (systemic side effects). May 10, 2016. Government of Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-eylea-aflibercept-assessing-risk-side-effects-outside-systemic-side.html
  • Berger, V., Munk, M. R., Lersch, F., Wolf, S., Ebneter, A., & Zinkernagel, M. S. (2019). Association of Intravitreal Injections With Blood Pressure Increase: The Following Excitement and Anxiety Response Under Intravitreal Injection Study. JAMA ophthalmology, 137(1), 87–90. https://doi.org/10.1001/jamaophthalmol.2018.4892
  • Eylea HD Prescribing Information. https://www.regeneron.com/downloads/eyleahd_fpi
  • Kahook, M. Y., Kimura, A. E., Wong, L. J., Ammar, D. A., Maycotte, M. A., & Mandava, N. (2009). Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye, 40(3), 293–295. https://doi.org/10.3928/15428877-20090430-12
    Copy

Read next

What is the difference between Vabysmo and Eylea?

Vabysmo (faricimab) targets vascular endothelial growth factor (VEGF) and angiopoietin-1, whereas Eylea (afibercept) targets VEGF and placental growth factor (P1GF). Both agents are used to treat conditions such as macular degeneration (AMD) and diabetic macular edema and are given by intravitreal injection (into the gel part of the eye). Continue reading

What’s the difference between Eylea, Eylea HD, and Avastin?

Eylea, Eylea HD, and Avastin may all be used to treat neovascular (wet) age-related macular degeneration (AMD), as injections into the eye (intravitreal injections). Both Eylea and Eylea HD are FDA-approved for this indication, but use of Avastin is off-label (not an FDA-approved indication - although it has been used for this purpose since 2005). Eylea HD is a longer acting version of Eylea. Continue reading

What are anti-VEGF drugs (VEGF inhibitors)?

Anti-VEGF drugs slow the abnormal growth of blood vessels associated with certain cancers and degenerative eye conditions, such as age-related macular degeneration. Anti-VEGF stands for anti-vascular endothelial growth factor. Continue reading

Related medical questions

Drug information

Related support groups